Microbot Stock Today

MBOT -  USA Stock  

USD 4.99  0.01  0.20%

Market Performance
0 of 100
Odds Of Distress
Less than 8
Microbot Medical is selling for under 4.99 as of the 26th of May 2022; that is 0.20% increase since the beginning of the trading day. The stock's last reported lowest price was 4.99. Microbot Medical has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Microbot Medical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of June 2020 and ending today, the 26th of May 2022. Click here to learn more.
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. The company has 7.11 M outstanding shares of which 121.73 K shares are now shorted by private and institutional investors with about 4.92 trading days to cover. More on Microbot Medical

Microbot Medical Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Microbot Medical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Microbot Medical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Microbot Medical generated a negative expected return over the last 90 days
Microbot Medical has high historical volatility and very poor performance
Microbot Medical was previously known as Stem Inc and was traded on New York Stock Exchange under the symbol STEM.
The company reported the previous year's revenue of 116.89 K. Net Loss for the year was (11.31 M) with profit before overhead, payroll, taxes, and interest of 6.63 M.
Microbot Medical currently holds about 15.49 M in cash with (9.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Microbot Medical has a frail financial position based on the latest SEC disclosures
Latest headline from www.fiercebiotech.com: Phillips ventilator foam recall linked to 124 deaths in one year - FierceBiotech
Microbot Medical Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Microbot Medical SEC Filings
Microbot Medical SEC Filings Security & Exchange Commission EDGAR Reports
Older SymbolSTEM
ChairmanHarel Gadot  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Microbot Medical report their recommendations after researching Microbot Medical's financial statements, talking to executives and customers, or listening in on Microbot Medical's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Microbot Medical. The Microbot consensus assessment is calculated by taking the average forecast from all of the analysts covering Microbot Medical.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Microbot Medical based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Microbot Medical financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares7.7 M7.1 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted7.7 M7.1 M
Significantly Up
Slightly volatile
Total Assets17.6 M16.8 M
Sufficiently Up
Total Liabilities2.4 M2.4 M
Fairly Up
Slightly volatile
Current Assets15.9 M15.9 M
Slightly Up
Very volatile
Current Liabilities2.8 MM
Significantly Up
Slightly volatile
Total Debt697.9 K680 K
Fairly Up
Gross Margin1.161.15
Slightly Up
Slightly volatile
Asset Turnover0.02430.0261
Significantly Down
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Microbot Medical's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Microbot Medical's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Microbot Medical's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Microbot Medical's financial leverage. It provides some insight into what part of Microbot Medical's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Microbot Medical's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Microbot Medical deploys its capital and how much of that capital is borrowed.
Microbot Medical cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 680 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Microbot Medical has a current ratio of 7.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Microbot Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Microbot Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Microbot Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Microbot to invest in growth at high rates of return. When we think about Microbot Medical's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(10.09 Million)Share
Microbot Medical (MBOT) is traded on NASDAQ Exchange in USA. It is located in 25 Recreation Park Drive and employs 20 people. Microbot Medical was previously known as Stem Inc and was traded on New York Stock Exchange under the symbol STEM. Microbot Medical is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 34.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Microbot Medical's market, we take the total number of its shares issued and multiply it by Microbot Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Microbot Medical conducts business under Healthcare sector and is part of Medical Instruments & Supplies industry. The entity has 7.11 M outstanding shares of which 121.73 K shares are now shorted by private and institutional investors with about 4.92 trading days to cover. Microbot Medical currently holds about 15.49 M in cash with (9.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Check Microbot Medical Probability Of Bankruptcy
The market capitalization of Microbot Medical is $34.47 Million. Microbot Medical secures 3.4 % if its outstanding shares held by insiders and 3.4 % owned by institutional investors . Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Microbot Ownership Details

Microbot Stock Price Odds Analysis

What are Microbot Medical's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Microbot Medical jumping above the current price in 90 days from now is about 87.29%. The Microbot Medical probability density function shows the probability of Microbot Medical stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Microbot Medical has a beta of 0.9812. This indicates Microbot Medical market returns are related to returns on the market. As the market goes up or down, Microbot Medical is expected to follow. Additionally, the company has an alpha of 0.0581, implying that it can generate a 0.0581 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 4.99HorizonTargetOdds Above 4.99
12.64%90 days
Based on a normal probability distribution, the odds of Microbot Medical to move above the current price in 90 days from now is about 87.29 (This Microbot Medical probability density function shows the probability of Microbot Stock to fall within a particular range of prices over 90 days) .

Microbot Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Microbot Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Microbot Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Microbot Medical's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares269.8 K1.7 M
Blackrock IncCommon Shares154.9 K971 K
View Microbot Medical Diagnostics

Microbot Medical Historical Income Statement

Microbot Medical Income Statement is one of the three primary financial statements used for reporting Microbot's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Microbot Medical revenue and expense. Microbot Medical Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Microbot Medical Interest Expense is comparatively stable at the moment as compared to the past year. Microbot Medical reported Interest Expense of 92,700 in 2021. Operating Expenses is likely to gain to about 12.2 M in 2022, whereas Gross Profit is likely to drop slightly above 761.7 K in 2022. View More Fundamentals

Microbot Stock Against Markets

Picking the right benchmark for Microbot Medical stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Microbot Medical stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Microbot Medical is critical whether you are bullish or bearish towards Microbot Medical at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Microbot Medical without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Microbot Medical Corporate Directors

Microbot Medical corporate directors refer to members of a Microbot Medical board of directors. The board of directors generally takes responsibility for the Microbot Medical's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Microbot Medical's board members must vote for the resolution. The Microbot Medical board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

Investing Microbot Medical

You need to understand the risk of investing before taking a position in Microbot Medical. The danger of trading Microbot Medical is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Microbot Medical is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Microbot Medical. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Microbot Medical is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Microbot Medical information on this page should be used as a complementary analysis to other Microbot Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Microbot Stock analysis

When running Microbot Medical price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is Microbot Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Microbot Medical. If investors know Microbot will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Microbot Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Microbot Medical is measured differently than its book value, which is the value of Microbot that is recorded on the company's balance sheet. Investors also form their own opinion of Microbot Medical's value that differs from its market value or its book value, called intrinsic value, which is Microbot Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Microbot Medical's market value can be influenced by many factors that don't directly affect Microbot Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Microbot Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine Microbot Medical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Microbot Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.